Accès ouvert
2025
article
OpenAlex
Yoichiro Narikawa, Atsuo Kuramasu, Masahiro Hosonuma, Masakazu Murayama et autres
Inosine, a bacterial metabolite and agonist of the adenosine A2A receptor, modulates antitumor immunity. However, its precise effects on immune checkpoint inhibitors remain unclear. This study aimed to evaluate the impact of inosine on the efficacy of anti-programmed cell death protein 1 …
jp, us
(code pays fourni par la source)
2025
article
OpenAlex
Kohei Tajima, Masahiro Hosonuma, Eiji Funayama, Junya Isobe et autres
Abstract The gut microbiome influences immune checkpoint inhibitor (ICI) efficacy. In this study, we explored the effects of combined levofloxacin (LVFX) and Clostridium butyricum MIYAIRI 588 (CBM588) on ICI outcomes using a CT26 tumor model in BALB/c mice. When compared with the …
jp, us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Yuya Hirasawa, Junya Isobe, Masahiro Hosonuma, Toshiaki Tsurui et autres
Introduction The rapid increase in the number of elderly patients with cancer necessitates treatment strategies based on the effects of aging because of drastic side effects of cytotoxic anticancer agents. Immune checkpoint inhibitors (ICIs) are relatively less toxic and can be easily …
jp, us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Yasunobu Amari, Masahiro Hosonuma, Takuya Mizukami, Junya Isobe et autres
ABSTRACT The concept of genome–microbiome interactions, in which the microenvironment determined by host genetic polymorphisms regulates the local microbiota, is important in the pathogenesis of human disease. In otolaryngology, the resident bacterial microbiota is reportedly altered in non-infectious ear diseases, such as …
jp, us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Eiji Funayama, Masahiro Hosonuma, Kohei Tajima, Junya Isobe et autres
Gut bacteria play pivotal roles in the antitumor effects of immune checkpoint inhibitors (ICIs). However, antimicrobial therapy, often necessary for infections in cancer patients, can reduce the efficacy of ICIs. The potential of probiotics to restore ICI efficacy remains uncertain. This study …
jp
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Hitoshi Toyoda, Atsuo Kuramasu, Masahiro Hosonuma, Masakazu Murayama et autres
Natural killer group 2 member D ligands (NKG2DLs) are expressed as stress response proteins in cancer cells. NKG2DLs induce immune cell activation or tumor escape responses, depending on their expression. Human pancreatic cancer cells, PANC-1, express membrane MHC class I polypeptide-related sequence …
jp
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Masakazu Murayama, Masahiro Hosonuma, Atsuo Kuramasu, Sei Kobayashi et autres
The low response rate of immune checkpoint inhibitors (ICIs) is a challenge. The efficacy of ICIs is influenced by the tumour microenvironment, which is controlled by the gut microbiota. In particular, intestinal bacteria and their metabolites, such as short chain fatty acids …
jp
(code pays fourni par la source)
Accès ouvert
2024
preprint
OpenAlex
Hitoshi Toyoda, Atsuo Kuramasu, Masahiro Hosonuma, Masakazu Murayama et autres
Abstract Natural killer group 2 member D ligands (NKG2DLs) are expressed as stress response proteins in cancer cells. NKG2DLs induce immune cell activation or tumor escape responses, depending on their expression. Human pancreatic cancer cells, PANC-1, express membrane MHC class I chain-related …
jp
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Masahiro Hosonuma, Yuya Hirasawa, Atsuo Kuramasu, Masakazu Murayama et autres
Immune checkpoint inhibitor discovery represents a turning point in cancer treatment. However, the response rates of solid tumors remain ~10%-30%; consequently, prognostic and immune-related adverse event (irAE) predictors are being explored. The programmed cell death protein 1 (PD-1) receptor occupancy (RO) of …
jp
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Kazuyuki Hamada, Junya Isobe, Kouya Hattori, Masahiro Hosonuma et autres
Introduction Immune checkpoint inhibitors have had a major impact on cancer treatment. Gut microbiota plays a major role in the cancer microenvironment, affecting treatment response. The gut microbiota is highly individual, and varies with factors, such as age and race. Gut microbiota …
jp
(code pays fourni par la source)